ClinicalTrials.gg
TerminatedNCT05996744Updated Feb 3, 2025Results posted

Study of Obeldesivir in Children and Adolescents With COVID-19

A Phase 2/3 interventional study of Obeldesivir in COVID-19, sponsored by Gilead Sciences. Terminated at 18 sites in United States. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2025-02-03.

Sponsored by Gilead Sciences · Phase 2/3, Interventional, and Treatment

Why this study was terminated
Study was terminated by Sponsor; the decision was not due to any safety findings.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
3
Allocation
Non-randomized
Ages
Up to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in COVID-19 by Gilead Sciences — none open to participants now, none under way, none of them phase 3. COVID-19 · Gilead Sciences.

Started
2023
with 1 other
Phase 2/3
2 of 10
none open now
Registered
10th of 10
by date

Among the 10 studies in COVID-19 by Gilead Sciences, this one is one of 2 that started in 2023, is one of 2 in phase 2/3, and was the 10th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

None of the 10 studies in COVID-19 by Gilead Sciences is open now. The open studies under COVID-19, anywhere →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: Up to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in COVID-19 by Gilead Sciences as a file.
02

Study summary

The goal of this clinical study is to learn more about the safety and tolerability of obeldesivir (ODV) in children and adolescents with coronavirus disease 2019 (COVID-19).

The primary objectives are to evaluate the plasma pharmacokinetics (PK), safety and tolerability of ODV in pediatric participants with COVID-19.

Read the detailed description

Pediatric participants will be enrolled as follows:

  • Cohort 1: ≥ 6 years to \< 18 years and weight ≥ 40 kg
  • Cohort 2: ≥ 6 years to \< 18 years and weight ≥ 20 kg to \< 40 kg
  • Cohort 3: ≥ 2 years to \< 18 years and weight ≥ 12 kg to \< 20 kg
  • Cohort 4: ≥ 28 days to \< 18 years and weight ≥ 3 kg to \< 12 kg
  • Cohort 5: ≥ 14 days to \< 28 days of age, gestational age (GA) ≥ 37 weeks and weight ≥ 2.5 kg
  • Cohort 6: 0 days to \< 14 days of age, GA ≥ 37 weeks and birth weight ≥ 2.5 kg
  • Cohort 7: 0 days to \< 56 days of age, GA \< 37 weeks and birth weight ≥ 1.5 kg
03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Individual or legal guardian willing and able to provide written prior to performing study procedures. Individuals will provide assent, if possible, in accordance with local requirements and investigator's discretion.
  • Aged \< 18 years who meet one of the following weight criteria and gestational age (GA) criteria where applicable:

    • Cohort 1: ≥ 6 years to \< 18 years and weight ≥ 40 kg
    • Cohort 2: ≥ 6 years to \< 18 years and weight ≥ 20 kg to \< 40 kg
    • Cohort 3: ≥ 2 years to \< 18 years and weight ≥ 12 kg to \< 20 kg
    • Cohort 4: ≥ 28 days to \< 18 years and weight ≥ 3 kg to \< 12 kg
    • Cohort 5: ≥ 14 days to \< 28 days of age, GA ≥ 37 weeks and weight ≥ 2.5 kg
    • Cohort 6: 0 days to \< 14 days of age, GA ≥ 37 weeks and birth weight ≥ 2.5 kg
    • Cohort 7: 0 days to \< 56 days of age, GA \< 37 weeks and birth weight ≥ 1.5 kg
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection confirmed by polymerase chain reaction (PCR) or an alternative molecular diagnostic assay ≤ 5 days before screening.
  • Initial onset of coronavirus disease 2019 (COVID-19) signs/symptoms ≤ 5 days before screening with ≥ 1 sign/symptom such as fever, cough, fatigue, shortness of breath, sore throat, headache, myalgia/arthralgia present at screening.
  • Presence of ≥ 1 characteristic or underlying medical condition associated with an increased risk of developing severe illness due to COVID-19 per protocol.

Key Exclusion Criteria:

  • Anticipated access to and use of authorized or approved COVID-19 therapies during the current COVID-19 illness \< 5 days after screening (therapies including but not limited to nirmatrelvir/ritonavir, molnupiravir, intravenous remdesivir (RDV), monoclonal antibodies).
  • Vaccination for SARS-CoV-2 or self-reported history of SARS-CoV-2 infection \< 4 months prior to screening.
  • Received any approved, authorized, or direct acting antiviral drug against SARS-CoV-2 for the treatment of COVID-19 \< 28 days or \< 5 half-lives, whichever is longer, before enrollment.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Obeldesivir (ODV) 350 mg Twice Daily, Cohort 1: ≥ 6 Years to < 18 Years and Weight ≥ 40 kg

    Participants received ODV tablets (350 mg twice daily) for 5 days.

    Drug: Obeldesivir

  • Experimental
    ODV 175 mg Twice Daily, Cohort 2: ≥ 6 Years to < 18 Years and Weight ≥ 20 kg to < 40 kg

    Participants received ODV tablets (175 mg twice daily) for 5 days.

    Drug: Obeldesivir

Interventions

  • Tablet administered orally with or without food

    Also known as: GS-5245

06

What researchers measure

Primary outcomes

  1. Plasma Concentration of GS-441524, Metabolite of Obeldesivir (ODV)

    Time frame: Day 3 (5 to 8 hours postdose) and Day 5 (predose and 15 minutes, 30 minutes, 1 hour, and 4 hours postdose)

  2. Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) by Day 35

    Treatment-emergent adverse events are defined as 1 or both of the following: * Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug * Any AEs leading to premature discontinuation of study drug.

    Time frame: First dose date up to Day 35

  3. Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities by Day 35

    Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study drug plus 30 days participants who permanently discontinued study drug.

    Time frame: First dose date up to Day 35

Secondary outcomes

  1. Time to Sustained Alleviation of Targeted Coronavirus Disease 2019 (COVID-19) Symptoms by Day 35

    The time to sustained alleviation of targeted COVID-19 symptoms will be calculated as the last date on which the symptom alleviation is assessed by Day 35 minus the first dose date plus 1 day or Day 34, whichever occurs first. Symptom alleviation is defined as follows: all targeted symptoms scored moderate or severe at baseline are scored as mild or none for at least 48 consecutive hours, and all targeted symptoms scored mild or none at baseline are scored as none for at least 48 consecutive hours; the first day of the 48 consecutive hours will be considered the symptom alleviation date. Targeted symptoms include: stuffy or runny nose, sore throat, shortness of breath, cough, low energy or tiredness, muscle or body aches, headache, chills or shivering, feeling hot or feverish, and nausea.

    Time frame: First dose date up to Day 35

  2. Change From Baseline in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load at Day 5

    Nasal swab samples will be used to assess SARS-CoV-2 viral load.

    Time frame: Baseline, Day 5

  3. Percentage of Participants Who Require Supplemental Oxygen Support by Day 35

    Supplemental oxygen support included low flow oxygen, high flow oxygen, noninvasive ventilation, mechanical ventilation, or extracorporeal membrane oxygenation.

    Time frame: First dose date up to Day 35

  4. Palatability for Each Formulation as Measured by Questionnaire Responses Assessed by the Study Participants

    A questionnaire was administered to participants to assess the palatability of the formulation. Palatability was assessed by questions about how the study drug tasted.

    Time frame: Day 5

  5. Acceptability for Each Formulation as Measured by Questionnaire Responses Assessed by the Study Participants

    A questionnaire was administered to participants to assess the acceptability of the formulation. Acceptability was assessed by questions about the size of the drug and how easy it was to swallow the study drug.

    Time frame: Day 5

  6. Percentage of Participants With Concomitant Use of Medications Other Than Remdesivir (RDV) and Obeldesivir (ODV) for Treatment of COVID-19 by Day 35

    Time frame: First dose date up to Day 35

  7. Percentage of Participants With COVID-19-Related Hospitalization or All-Cause Death by Day 35

    Time frame: First dose date up to Day 35

07

Results

Posted Feb 3, 2025

Participant flow

Participants were enrolled at study sites in the United States. The study was terminated early after 3 participants were enrolled. The decision to terminate the study early was not due to any safety concerns.

Participant flow — Overall Study
MilestoneObeldesivir (ODV) 350 mg Twice Daily, Cohort 1: ≥ 6 Years to < 18 Years and Weight ≥ 40 kgODV 175 mg Twice Daily, Cohort 2: ≥ 6 Years to < 18 Years and Weight ≥ 20 kg to < 40 kg
Started21
Completed21
Not completed00

Outcome measures

PrimaryPlasma Concentration of GS-441524, Metabolite of Obeldesivir (ODV)
Time frame:
Day 3 (5 to 8 hours postdose) and Day 5 (predose and 15 minutes, 30 minutes, 1 hour, and 4 hours postdose)
Reported as:
Mean · ng/mL
Plasma Concentration of GS-441524, Metabolite of Obeldesivir (ODV)
ng/mLObeldesivir (ODV) 350 mg Twice Daily, Cohort 1: ≥ 6 Years to < 18 Years and Weight ≥ 40 kgODV 175 mg Twice Daily, Cohort 2: ≥ 6 Years to < 18 Years and Weight ≥ 20 kg to < 40 kg
Day 3 (5 to 8 hours postdose)1950 ± 933NA ± NA
Day 5 (predose)79.2 ± 97.3NA ± NA
Day 5 (15 minutes postdose)8.37 ± NA209 ± NA
Day 5 (30 minutes postdose)14.5 ± NA—
Day 5 (1 hour postdose)510 ± NA—
Day 5 (4 hours postdose)1610 ± NA—
PrimaryPercentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) by Day 35

Treatment-emergent adverse events are defined as 1 or both of the following: * Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug * Any AEs leading to premature discontinuation of study drug.

Time frame:
First dose date up to Day 35
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) by Day 35
percentage of participantsObeldesivir (ODV) 350 mg Twice Daily, Cohort 1: ≥ 6 Years to < 18 Years and Weight ≥ 40 kgODV 175 mg Twice Daily, Cohort 2: ≥ 6 Years to < 18 Years and Weight ≥ 20 kg to < 40 kg
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) by Day 3500
PrimaryPercentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities by Day 35

Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study drug plus 30 days participants who permanently discontinued study drug.

Time frame:
First dose date up to Day 35
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities by Day 35
percentage of participantsObeldesivir (ODV) 350 mg Twice Daily, Cohort 1: ≥ 6 Years to < 18 Years and Weight ≥ 40 kgODV 175 mg Twice Daily, Cohort 2: ≥ 6 Years to < 18 Years and Weight ≥ 20 kg to < 40 kg
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities by Day 3500
SecondaryTime to Sustained Alleviation of Targeted Coronavirus Disease 2019 (COVID-19) Symptoms by Day 35

The time to sustained alleviation of targeted COVID-19 symptoms will be calculated as the last date on which the symptom alleviation is assessed by Day 35 minus the first dose date plus 1 day or Day 34, whichever occurs first. Symptom alleviation is defined as follows: all targeted symptoms scored moderate or severe at baseline are scored as mild or none for at least 48 consecutive hours, and all targeted symptoms scored mild or none at baseline are scored as none for at least 48 consecutive hours; the first day of the 48 consecutive hours will be considered the symptom alleviation date. Targeted symptoms include: stuffy or runny nose, sore throat, shortness of breath, cough, low energy or tiredness, muscle or body aches, headache, chills or shivering, feeling hot or feverish, and nausea.

Time frame:
First dose date up to Day 35
Reported as:
Mean · Days
Time to Sustained Alleviation of Targeted Coronavirus Disease 2019 (COVID-19) Symptoms by Day 35
DaysObeldesivir (ODV) 350 mg Twice Daily, Cohort 1: ≥ 6 Years to < 18 Years and Weight ≥ 40 kgODV 175 mg Twice Daily, Cohort 2: ≥ 6 Years to < 18 Years and Weight ≥ 20 kg to < 40 kg
Time to Sustained Alleviation of Targeted Coronavirus Disease 2019 (COVID-19) Symptoms by Day 353.4 ± 0.472.5 ± NA
SecondaryChange From Baseline in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load at Day 5

Nasal swab samples will be used to assess SARS-CoV-2 viral load.

Time frame:
Baseline, Day 5
Reported as:
Mean · log10 copies/mL
Change From Baseline in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load at Day 5
log10 copies/mLObeldesivir (ODV) 350 mg Twice Daily, Cohort 1: ≥ 6 Years to < 18 Years and Weight ≥ 40 kgODV 175 mg Twice Daily, Cohort 2: ≥ 6 Years to < 18 Years and Weight ≥ 20 kg to < 40 kg
Change From Baseline in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load at Day 5-0.61 ± 0.868NA ± NA
SecondaryPercentage of Participants Who Require Supplemental Oxygen Support by Day 35

Supplemental oxygen support included low flow oxygen, high flow oxygen, noninvasive ventilation, mechanical ventilation, or extracorporeal membrane oxygenation.

Time frame:
First dose date up to Day 35
Reported as:
Number · percentage of participants
Percentage of Participants Who Require Supplemental Oxygen Support by Day 35
percentage of participantsObeldesivir (ODV) 350 mg Twice Daily, Cohort 1: ≥ 6 Years to < 18 Years and Weight ≥ 40 kgODV 175 mg Twice Daily, Cohort 2: ≥ 6 Years to < 18 Years and Weight ≥ 20 kg to < 40 kg
Percentage of Participants Who Require Supplemental Oxygen Support by Day 3500
SecondaryPalatability for Each Formulation as Measured by Questionnaire Responses Assessed by the Study Participants

A questionnaire was administered to participants to assess the palatability of the formulation. Palatability was assessed by questions about how the study drug tasted.

Time frame:
Day 5
Reported as:
Count of participants · Participants
Palatability for Each Formulation as Measured by Questionnaire Responses Assessed by the Study Participants
ParticipantsObeldesivir (ODV) 350 mg Twice Daily, Cohort 1: ≥ 6 Years to < 18 Years and Weight ≥ 40 kgODV 175 mg Twice Daily, Cohort 2: ≥ 6 Years to < 18 Years and Weight ≥ 20 kg to < 40 kg
No Taste10
Neutral Taste (Maybe Good or Maybe Bad)11
SecondaryAcceptability for Each Formulation as Measured by Questionnaire Responses Assessed by the Study Participants

A questionnaire was administered to participants to assess the acceptability of the formulation. Acceptability was assessed by questions about the size of the drug and how easy it was to swallow the study drug.

Time frame:
Day 5
Reported as:
Count of participants · Participants
Acceptability for Each Formulation as Measured by Questionnaire Responses Assessed by the Study Participants
ParticipantsObeldesivir (ODV) 350 mg Twice Daily, Cohort 1: ≥ 6 Years to < 18 Years and Weight ≥ 40 kgODV 175 mg Twice Daily, Cohort 2: ≥ 6 Years to < 18 Years and Weight ≥ 20 kg to < 40 kg
Super Easy to Swallow10
Easy to Swallow10
Hard to Swallow01
Size: Okay21
SecondaryPercentage of Participants With Concomitant Use of Medications Other Than Remdesivir (RDV) and Obeldesivir (ODV) for Treatment of COVID-19 by Day 35
Time frame:
First dose date up to Day 35
Reported as:
Number · percentage of participants
Percentage of Participants With Concomitant Use of Medications Other Than Remdesivir (RDV) and Obeldesivir (ODV) for Treatment of COVID-19 by Day 35
percentage of participantsObeldesivir (ODV) 350 mg Twice Daily, Cohort 1: ≥ 6 Years to < 18 Years and Weight ≥ 40 kgODV 175 mg Twice Daily, Cohort 2: ≥ 6 Years to < 18 Years and Weight ≥ 20 kg to < 40 kg
Percentage of Participants With Concomitant Use of Medications Other Than Remdesivir (RDV) and Obeldesivir (ODV) for Treatment of COVID-19 by Day 3500
SecondaryPercentage of Participants With COVID-19-Related Hospitalization or All-Cause Death by Day 35
Time frame:
First dose date up to Day 35
Reported as:
Number · percentage of participants
Percentage of Participants With COVID-19-Related Hospitalization or All-Cause Death by Day 35
percentage of participantsObeldesivir (ODV) 350 mg Twice Daily, Cohort 1: ≥ 6 Years to < 18 Years and Weight ≥ 40 kgODV 175 mg Twice Daily, Cohort 2: ≥ 6 Years to < 18 Years and Weight ≥ 20 kg to < 40 kg
Percentage of Participants With COVID-19-Related Hospitalization or All-Cause Death by Day 3500

Adverse events

Collected over Up to 35 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Obeldesivir (ODV) 350 mg Twice Daily, Cohort 1: ≥ 6 Years to < 18 Years and Weight ≥ 40 kg0/2 (0%)0/2 (0%)0/2 (0%)
ODV 175 mg Twice Daily, Cohort 2: ≥ 6 Years to < 18 Years and Weight ≥ 20 kg to < 40 kg0/1 (0%)0/1 (0%)0/1 (0%)

Baseline characteristics

All participants who enrolled in the study and received the study drug were included.

Age, Customized
Age, Customized(Participants)Obeldesivir (ODV) 350 mg Twice Daily, Cohort 1: ≥ 6 Years to < 18 Years and Weight ≥ 40 kgODV 175 mg Twice Daily, Cohort 2: ≥ 6 Years to < 18 Years and Weight ≥ 20 kg to < 40 kgTotal
≥ 6 years to < 18 years213
Sex: Female, Male
Sex: Female, Male(Participants)Obeldesivir (ODV) 350 mg Twice Daily, Cohort 1: ≥ 6 Years to < 18 Years and Weight ≥ 40 kgODV 175 mg Twice Daily, Cohort 2: ≥ 6 Years to < 18 Years and Weight ≥ 20 kg to < 40 kgTotal
Female000
Male213
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Obeldesivir (ODV) 350 mg Twice Daily, Cohort 1: ≥ 6 Years to < 18 Years and Weight ≥ 40 kgODV 175 mg Twice Daily, Cohort 2: ≥ 6 Years to < 18 Years and Weight ≥ 20 kg to < 40 kgTotal
Hispanic or Latino213
Not Hispanic or Latino000
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Obeldesivir (ODV) 350 mg Twice Daily, Cohort 1: ≥ 6 Years to < 18 Years and Weight ≥ 40 kgODV 175 mg Twice Daily, Cohort 2: ≥ 6 Years to < 18 Years and Weight ≥ 20 kg to < 40 kgTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White213
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Obeldesivir (ODV) 350 mg Twice Daily, Cohort 1: ≥ 6 Years to < 18 Years and Weight ≥ 40 kgODV 175 mg Twice Daily, Cohort 2: ≥ 6 Years to < 18 Years and Weight ≥ 20 kg to < 40 kgTotal
United States213
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load(log10 copies/mL)Obeldesivir (ODV) 350 mg Twice Daily, Cohort 1: ≥ 6 Years to < 18 Years and Weight ≥ 40 kgODV 175 mg Twice Daily, Cohort 2: ≥ 6 Years to < 18 Years and Weight ≥ 20 kg to < 40 kgTotal
Mean3.57 ± 0.9914.36 ± NA3.84 ± 0.836
08

Study locations

18 sites
  • Trinity Clinical Research, LLC
    Centreville, Alabama 35042, United States
  • Advanced Research Center, Inc.
    Anaheim, California 92805, United States
  • Stanford University Medical Center
    Palo Alto, California 94304, United States
  • UF Health- Shands Hospital
    Gainesville, Florida 32610, United States
  • Encore Medical Research LLC
    Hollywood, Florida 33021, United States
  • Accel Research Sites Network - Nona Pediatric Center
    Orlando, Florida 32829, United States
  • Avanza Medical Research Center
    Pensacola, Florida 32503, United States
  • Santos Research Center
    Tampa, Florida 33603, United States
  • Pas Research
    Tampa, Florida 33613, United States
  • Velocity Clinical Research, Norfolk
    Norfolk, Nebraska 68701, United States
  • Velocity Clinical Research, Omaha
    Omaha, Nebraska 68134, United States
  • Pas Research
    Las Vegas, Nevada 89128, United States
  • Velocity Clinical Research -Albuquerque
    Albuquerque, New Mexico 87107, United States
  • Child Health Care Associates
    East Syracuse, New York 13057, United States
  • Velocity Clinical Research, Charleston
    Charleston, South Carolina 29414, United States
  • PanAmerican Clinical Research, LLC
    Brownsville, Texas 78520, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
  • The University of Texas Medical School at Houston
    Houston, Texas 77030, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in Feb 2024, 1 month.

Results were first posted in Feb 2025, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2023
First posted
Aug 18, 2023
StartActual
Dec 26, 2023
Primary completionActual
Feb 23, 2024
CompletionActual
Feb 23, 2024
Results first posted
Feb 3, 2025
Last update
Feb 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05996744
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Aug 18, 2023
Start date
Dec 26, 2023
Primary completion
Feb 23, 2024
Completion
Feb 23, 2024
Results posted
Feb 3, 2025
Last update
Feb 3, 2025

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Obeldesivir

Start the discussion